NCT06984250 Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
| NCT ID | NCT06984250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Early Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 315 participants |
| Start Date | 2025-02-06 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 315 participants in total. It began in 2025-02-06 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Eligibility Criteria
Inclusion Criteria: * Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS). * Patients undergoing breast-conserving surgery * Age ≥ 20 years * Karnofsky Performance Status (KPS) ≥70% * Life expectancy ≥ 5 years * Adequate renal and hepatic function Exclusion Criteria: * Pregnant patients * Patients requiring re-irradiation of the thoracic region
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06984250 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 85 Years, studying Early Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06984250 currently recruiting?
Yes, NCT06984250 is actively recruiting participants. Contact the research team at nickliucool@ntuh.gov.tw for enrollment information.
Where is the NCT06984250 trial being conducted?
This trial is being conducted at Taipei, Taiwan, Taipei, Taiwan.
Who is sponsoring the NCT06984250 clinical trial?
NCT06984250 is sponsored by National Taiwan University Hospital. The trial plans to enroll 315 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.